Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Inclusion Criteria

• •Any solid tumor that failed standard therapy.
• •Patient must have evidence for tumor by CT, MRI, PET scan, MIBG scan, serum markers, or tissue sampling.
• •Age ≤ 21 years.
• •Karnofsky/Lansky performance status ≥ 50% (Karnofsky score for age\> 16 years and Lansky score for age ≤ 16 years)
• •ANC≥ 1000 at least 24 hours off GCSF
• •Platelets ≥ 75k at least one week off platelet transfusions
• •Hg≥ 8g/dL at least one week off PRBC transfusion
• •AST ≤ 3 x the upper limit of normal
• •ALT ≤ 3 x the upper limit of normal
• •Total bilirubin ≤ 2.0 mg/dl
• •serum creatinine ≤ 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR ≥ 70 ml/min/1.73 m2.
• •≥ 3 weeks since last non-nitrosourea chemotherapy
• •≥ 6 weeks since last nitrosoureas
• •≥ 4 weeks since last RT
• •Patients must agree to practice adequate contraception. Females of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to drug initiation. Females must not be breast feeding.
• •Patients must be able to swallow tablets whole